The importance of chemotherapy has also been confirmed for patients with HER2-positive advanced/metastatic gastric cancer in the randomized IIT phase II INTEGA (LBA54) AIO-trial,2 in which the combination of trastuzumab, nivolumab, and FOLFOX showed increased efficacy with 70% OS rate at 12 months. This evidence concerns the gene ERBB2 and gastric cancer.